Volume 19, Number 3—March 2013
Research
Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010
Table 7
Sensitivity analyses showing estimates of clinical cases prevented by acceleration of vaccination against influenza A(H1N1)pdm09 virus*
Dates of vaccination program | Point estimate | Range |
---|---|---|
Hypothetical dates | ||
2009 Aug 08–2010 21 Feb | 4,176,031 | 2,974,975–5,970,682 |
2009 Aug 15–2010 28 Feb | 3,742,600 | 2,674,232–5,322,588 |
2009 Aug 22–2010 07 Mar | 3,299,591 | 2,366,468–4,668,558 |
2009 Aug 29–2010 14 Mar | 2,855,894 | 2,054,754–4,020,843 |
2009 Sep 05–2010 21 Mar | 2,422,481 | 1,747,781–3,398,603 |
2009 Sep 12–2010 28 Mar | 2,010,198 | 1,450,291–2,817,245 |
2009 Sep 19–2010 04 Apr | 1,633,200 | 1,171,673–2,292,018 |
2009 Sep 26–2010 11 Apr |
1,303,621 |
922,931–1,836,514 |
Actual dates | ||
2009 Oct 03–2010 18 Apr† | 1,029,157 | 712,908–1,458,930 |
*The epidemic curve that was used to generate these estimates was the base case estimate, which was based on the assumption that a vaccination program did not exist. Data reflect calculations made for scenario 5 by estimating effects of moving the start date of the program to begin 8 weeks to 1 week earlier.
†See Table 2, Appendix, wwwnc.cdc.gov/EID/article/19/3/12-0394-T2.htm.
1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.